| 摘要 |
X-ray contrast compositions having improved cardiac and systemic safety containing approximately 34 to 40% iodine and suitable for use in angiocardiographic procedures comprise an aqueous solution of a mixture of a nonionic X-ray contrast medium and an ionic X-ray contrast medium, the composition having a viscosity of not more than approximately 9-12 centipoises at 37 DEG C, the nonionic X-ray a contrast medium per se in aqueous solution having a viscosity greater than that of the composition at 37 DEG C, and the ionic X-ray contrast medium per se in aqueous solution having a viscosity of less than that of the composition at 37 DEG C. The ionic contrast agents include the pharmaceutically acceptable salts 4 (e.g., sodium, N-methylglucamine etc.) of iothalamic acid (5-acetamido- 2,4,6-triodo-N-methylisophthalamic acid), diatrizoic acid (3,5-diacetamido- 2,4,6-triiodobenzoic acid), ioxaglic acid (2,4,6-triiodo-3-N-hydroxyethylcarbamyl- 5-(2,4, 6-triiodo- 3-N-methylcarbamyl-5-N-methyl-N- acetylaminobenzoyl)glycylaminobenzoic acid, U.S. patent No. 4,065,554), metrizoic acid (3(acetylamino)- 5-(acetylmethylamino)- 2,4,6-triiodobenzoic acid), ioxithalamic acid (5-acetamido-2,4,6-triiodo- N-2-hydroxyethyl isophthalamic acid) and iodamide (3-(acetylamino)- 5-[(acetylamino)methyl]- 2,4,6-triiodobenzoic acid). The non- ionic contrast agents include N,N'- bis-(2,3-dihydroxypropyl)-2,4,6-triiodo- 5-(2-keto-L-gulonamido) isophtalamide, N-(2-hydroxyethyl)- 2,4,6-triiodo-bis-3,5-(2-keto-L-gulonamido) benzamide, L-5- alpha -hydroxypropionylamino- 2,4,6-triiodoisophtalic acid di-(1,3-dihydroxyisopropylamide) and 5-(N-2-hydroxyethylacetamido)- 2,4,6-triiodo-N,N'- bis-2,3-dihydroxypropyl)-isophthalamide, N-(N-methyl-3,5-diacetamido- 2,4,6-triiodobenzoyl)-glucosamine and 3,5-bis-gluconamido-2,4,6- triiodo-N-methylbenzamide. |
